TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study for the Treatment of the Bone Marrow Edema:Core Decompression VS Bone Marrow Concentrate (BMC) VS Bone Substitute

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients between 18 and 75 years;~2. Symptomatic subchondral bone marrow lesions of femoral condyles (grade ≥ 1 according to the WORMS MRI score);~3. Failure after at least two months of a conservative treatment;~4. Single BME areas involving a single compartment of the knee;~5. Availability of the patients to participate actively in the rehabilitation protocol and follow-up clinic and radiology;~6. Signature of informed consent.~Exclusion Criteria:~1. Patients incapable of discernment;~2. History of allergy to calcium phosphates;~3. Patients with malignancies;~4. Patients with rheumatic diseases;~5. Patients with diabetes;~6. Patients suffering of metabolic disorders of the thyroid;~7. Patients with history of abuse of alcohol, drugs or medication;~8. Patients with advanced osteoarthritis (Kellgren-Lawrence grade\> 3);~9. Body Mass Index\> 35;~10. BME that involve more than one compartment;~11. Patients with trauma in the 6 months prior to the intervention. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- core decompression technique (Type: ACTIVE_COMPARATOR): The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
- bone substitution (i-FactorTM) (Type: EXPERIMENTAL): i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
- injections of autologous Bone Marrow Concentrate (BMC) (Type: EXPERIMENTAL): injections of autologous BMC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old to 65 years old, diagnosis of primary headache~Exclusion Criteria:~* Allergy to study medications, pregnant, breast-feeding, prisoners, non-english speaking, not eligible to receive droperidol based on ED protocol (see below), patients in whom head trauma, infection, vascular disorders, and disorders of facial or cranial structures are suspected~ED Droperidol Protocol~Droperidol must NOT be used in patients with any of the following:~* Known or suspected QT prolongation, including congenital long QT syndrome~* Cardiac Disease \[cardiomyopathy, congestive heart failure, hypertension, ischemic heart disease, myocardial infarction, bradycardia (\< 50 bpm)\]~* History of the following:~  * Renal failure~ * Cerebrovascular disease~ * Diabetes or hypoglycemia~ * Alcoholism/alcohol abuse~ * Pituitary insufficiency~ * Hypothyroidism~ * Hypothermia~ * Anorexia~* Advanced age (\>65 yrs)~* Use of the following medications: digoxin, benzodiazepine, diuretics, IV opiates, or other medications known to prolong the QTc interval.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Droperidol (Type: EXPERIMENTAL): None
- Metoclopramide + Diphenhydramine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mast Cells in Acid-induced Intestinal Permeability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy~Exclusion Criteria:~* - refused informed consent~* pregnant women or women who are breastfeeding~* symptoms or history of gastrointestinal disease~* diabetes mellitus~* coagulation disorders/anticoagulant therapy~* first degree relatives with celiac disease, Crohn's disease or type I diabetes mellitus~* taking antihistamines, ketotifen, cromoglycate, acetylsalicylates, NSAIDs, anticholinergics, theophylline, β2-agonists, codeine or opioid derivatives 2 weeks prior to the study~* taking steroid or immunosuppressive drugs 6 months prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): mannitol
- disodium cromoglycate (Type: ACTIVE_COMPARATOR): disodium cromoglycate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria~1. Biopsy-confirmed NASH diagnosis with CRN score of fibrosis stage of F1 to F3 within the previous 12 months prior to screening or history of fatty liver disease by imaging plus clinical suspicion of NASH based on history of type 2 DM for at least 5 years or overweight/obesity with BMI 25 to 40 kg/m\^2 with 2 additional metabolic syndrome components.~2. Males and females of non-child bearing potential.~3. Willing to provide written informed consent and comply with study requirements.~Key Exclusion Criteria~1. Evidence of any clinical important condition which in the investigator opinion makes it undesirable for the participant to participate in the study~2. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention~3. History of liver transplant or presence or history of hepatic disease other than NASH or histological or imaging evidence of cirrhosis.~4. Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B (HBV)virus, seropositive for Hepatitis C virus (HCV)~5. History of excessive alcohol consumption~6. Uncontrolled high blood pressure~7. Any clinically important abnormalities in ECG~8. Suspected history of illicit drug abuse~9. Clinically important abnormalities in urine and blood laboratory results~10. Changes in concomitant medication within 1 month of screening~11. Received another investigational drug within 90 days of administration of study intervention in this study~12. Has received any chemical entity or investigational drug targeting HSD17B13 (eg, ARO-HSD or ALN-HSD).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: OTHER): Dose A cohort: 20 participants; n=15 on AZD7503 dose A, n=5 on Placebo
- Cohort 2 (Type: OTHER): Dose B cohort: 20 participants; n=15 on AZD7503 dose B, n=5 on Placebo.
- Cohort 3 (Type: OTHER): Dose C cohort: 20 participants n=15 on AZD7503 dose C, n=5 on Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Scheduled for SAVR or TAVR~* Age \> 18 years~* Able and willing to give informed consent~* Able and willing to return for follow up~Exclusion Criteria:~* Contraindications to warfarin, Plavix or aspirin~* Pre-existing medical indication for warfarin, Plavix or aspirin~* History of previous cardiac surgery~* History of previous coronary artery stenting~* Requirement for concomitant coronary artery bypass grafting or mitral valve surgery or surgical treatment of an ascending aortic aneurysm~* Contraindications to contrast-enhanced MDCT including anaphylactic iodine allergy, uncontrolled atrial fibrillation, renal dysfunction (GFR \< 60 ml/min).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAVR Warfarin Arm (Type: EXPERIMENTAL): Warfarin arm-(target INR of 2-3)
- TAVR Warfarin and Clopidogrel Arm (Type: EXPERIMENTAL): Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
- SAVR Aspirin Arm (Type: EXPERIMENTAL): Aspirin arm (81mg/day)
- TAVR Aspirin and Clopidogrel Arm (Type: EXPERIMENTAL): Aspirin (81mg/day) and Clopidogrel (75mg/day) arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced, measurable metastatic esophagogastric adenocarcinoma by RECIST criteria~* Patients who have had surgery or radiotherapy with or without neoadjuvant or adjuvant chemotherapy (the wash-out period will be at least 1 month)~* Patients who are not eligible for resection and are chemotherapy naïve~* Patients with HER2(-) status~* Patients who have tumor deposit(s) that are easily accessible by ultrasound or CT guidance~* Patients must have adequate organ function~* Patients must provide written informed consent~Exclusion Criteria:~* Active concurrent malignancy, other than superficial, non-squamous cell carcinoma of the skin or uterine cervix, within the past three years~* ECOG performance status worse than 2~* Prior oral or intravenous chemotherapy for metastatic disease~* Patients with comorbidities that prevent them from being able to receive the chemotherapy regimen~* cardiac ejection fraction 45% or greater

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): Standard chemotherapy doublet based on molecular testing using one of the following interventions:~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with GERD grade A and B (mild to moderate severe disease) diagnosed by routine endoscopy will be recruited in different clinical and ambulant centres of gastroenterology; written informed consent is obligatory~* Range of Age: 20-70~* BMI: 20-30~Exclusion Criteria:~* Patients who are allergic to proton-pump inhibitors or show incompatibility~* Patients who have lactase deficiency~* Patients who have severe chronic disease~* Patients who participated in another study during the last three months~* Patients who are pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: ACTIVE_COMPARATOR): 3 tablets, only 20 mg omeprazole, genotype independent
- intervention group (Type: ACTIVE_COMPARATOR): 20 vs. 60 mg daily, genotype dependent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed unresectable or metastatic cancer Confirmed by biopsy or fine needle aspiration Tumors must predominantly involve the lung Measurable or evaluable disease No lymphomas or leukemias No AIDS associate Kaposi's Sarcoma No uncontrolled brain metastases~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-1 Life expectancy: At least 3 months Hematopoietic: WBC at least 4,000/mm3 Platelet count within normal limits Hepatic: Bilirubin no greater than 2 times normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: Adequate cardiovascular system with NYHA Class 0 or I No uncontrolled cardiac arrhythmias Pulmonary: FEV1 at least 65% of predicted FVC at least 65% of predicted No asthma or bronchial obstruction that would prevent the delivery of IL-2 to all lobes of the lung Other: HIV negative No medical or psychological criteria that would make patient unable to tolerate the treatment Not pregnant or nursing Adequate contraception required of all fertile patients~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interleukin-2 Prior biologic response therapy allowed No chronic use of immunosuppressive medicines Chemotherapy: Prior chemotherapy allowed Endocrine therapy: No chronic steroid use Prior hormonal therapy allowed Radiotherapy: No prior or concurrent radiotherapy except as palliative to areas of painful metastases outside the lung Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Myocet Plus Endoxan for Older Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed metastatic breast adenocarcinoma~* No more than one prior therapy regimen (other than hormonal therapy) for metastatic breast cancer is acceptable.~* Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)~* Performance status (WHO) 0-2~* Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases)~* Adequate renal function (serum creatinine \<1.5 times the upper normal limit)~* Adequate cardiac function (LVEF within normal limits)~* Adequate bone marrow function (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L)~* No radiation of measurable disease (except brain metastases)~* No progressive brain metastases according to clinical or radiological criteria~* No brain metastases without prior radiation therapy~* Written informed consent~Exclusion Criteria:~* Active infection~* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)~* Prior treatment with an anthracycline-containing regimen (as adjuvant therapy) during the previous 12 months period~* Other invasive malignancy except non-melanoma skin cancer~* Psychiatric illness or social situation that would preclude study compliance~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Cyclofosfamide/Liposomal-encapsulated doxorubicin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy research participants of both sexes (male and female non-pregnant), aged 18 years or over, underwent impacted third molar extraction surgery~Exclusion Criteria:~* Presence of any event and / or pathology at the site of interest that may interfere with and contraindicate the performance of the surgical procedure at the discretion of the Investigator, including periodontitis, odontogenic tumors or cysts (associated or not with the third molar), trauma, presence of Inflammation and / or infection;~* Present or past history of any cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric, hematological event;~* Previous diagnosis of alcohol and drug abuse defined by DSM-V;~* Current or past history (for less than 12 months) of smoking;~* Use of illicit drugs;~* History of bleeding / bleeding or coagulation disorders, gastric ulcer and / or active peptic hemorrhage;~* Any finding of clinical (clinical / physical), laboratory or cardiac evaluation (ECG) observation that is interpreted by the investigating physician as a risk to the participant;~* Use of drugs that potentially interfere with the kinetics / dynamics of acetaminophen or any other medicinal product considered clinically significant by the Investigator;~* Known hypersensitivity to the active principles used during the study (etodolac and cyclobenzaprine);~* Women in gestation or breastfeeding, as well as women who present a positive pregnancy test (β - hCG) during the study screening / selection period;~* Professionals directly involved in the realization of the present study and their relatives;~* Participant of the research that has participated in clinical study protocols in the last 12 (twelve) months, unless the Investigator deems that there may be direct benefit to it.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): 1 active treatment (Fixed Dose Combination) + 2 placebos
- Group 2 (Type: ACTIVE_COMPARATOR): 1 active treatment (Cyclobenzaprine) + 2 placebos
- Group 3 (Type: ACTIVE_COMPARATOR): 1 active treatment (Etodolac) + 2 placebos

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide in Patients With Immune Mediated Enteropathies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patients will be recruited from the Division of Gastroenterology and Hepatology and the Mayo Clinic in Rochester, MN.~* Adult patients with immune mediated enteropathies who have had improvement in symptoms and histology on oral budesonide therapy.~Exclusion Criteria~* Age \<18 years~* Positive stool gluten testing in patients with refractory celiac disease~* Small bowel malignancy or history of small bowel malignancy~* Refractory celiac disease type 2~* Post-transplant lymphoproliferative disorder associated enteropathy~* No prior improvement in symptoms and histology with budesonide therapy~* Discontinuation of budesonide therapy prior to the trial~* Other concurrent systemic corticosteroids~* Other immune mediating medications, for example but not limited to azathioprine, 6-mercaptopurine, cyclosporine, methotrexate, anti-TNF monoclonal antibodies, alpha-4 beta-7 integrin inhibiting monoclonal antibody, interleukin 12/23 inhibiting monoclonal antibody, JAK inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continued Budesonide (Type: NO_INTERVENTION): Patients in this arm continue budesonide at the dose they were taking at the time of enrollment in the trial
- Withdrawal of Budesonide (Type: EXPERIMENTAL): Patients are weaned off of budesonide over 2 weeks and continued off of the medication for the duration of the trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues